Imperial College London
Portrait Picture

ProfessorJustinStebbing

Faculty of Medicine, Department of Surgery & Cancer

Visiting Professor
 
 
 
//

Contact

 

j.stebbing Website CV

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pallett:2021:10.1038/s41598-021-85247-w,
author = {Pallett, SJC and Denny, S and Patel, A and Charani, E and Mughal, N and Stebbing, J and Davies, G and Moore, L},
doi = {10.1038/s41598-021-85247-w},
journal = {Scientific Reports},
pages = {1--8},
title = {Point-of-care SARS-CoV-2 serological assays for enhanced case finding in a UK inpatient population.},
url = {http://dx.doi.org/10.1038/s41598-021-85247-w},
volume = {11},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Case identification is currently made by real-time polymerase chain reaction (PCR) during the acute phase and largely restricted to healthcare laboratories. Serological assays are emerging but independent validation is urgently required to assess their utility. We evaluated five different point-of-care (POC) SARS-CoV-2 antibody test kits against PCR, finding concordance across the assays (n=15). We subsequently tested 200 patients using the OrientGene COVID-19 IgG/IgM Rapid Test Cassette and find a sensitivity of 74% in the early infection period (day 5-9 post symptom onset), with 100% sensitivity not seen until day 13, demonstrating inferiority to PCR testing in the infectious period. Negative rate was 96%, but in validating the serological tests uncovered potential false-negatives from PCR testing late-presenting cases. A positive predictive value (PPV) of 37% in the general population precludes any use for general screening. Where a case definition is applied however, the PPV is substantially improved (95·4%), supporting use of serology testing in carefully targeted, high-risk populations. Larger studies in specific patient cohorts, including those with mild infection are urgently required to inform on the applicability of POC serological assays to help control the spread of SARS-CoV-2 and improve case finding of patients that may experience late complications.
AU  - Pallett,SJC
AU  - Denny,S
AU  - Patel,A
AU  - Charani,E
AU  - Mughal,N
AU  - Stebbing,J
AU  - Davies,G
AU  - Moore,L
DO  - 10.1038/s41598-021-85247-w
EP  - 8
PY  - 2021///
SN  - 2045-2322
SP  - 1
TI  - Point-of-care SARS-CoV-2 serological assays for enhanced case finding in a UK inpatient population.
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-021-85247-w
UR  - https://www.nature.com/articles/s41598-021-85247-w
UR  - http://hdl.handle.net/10044/1/86230
VL  - 11
ER  -
Download